Search
P-42 peptide
go.drugbank.com/drugs/DB18610ExperimentalP-42 peptide is a synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein
Talquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigationalIt consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. … [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]
CYT006-AngQb
go.drugbank.com/drugs/DB05739InvestigationalIt is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.
Eugenol
go.drugbank.com/drugs/DB09086ApprovedInvestigationalEugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves.
Pyrazinamide
go.drugbank.com/drugs/DB00339ApprovedInvestigationalA pyrazine that is used therapeutically as an antitubercular agent.
Mixtures: AKURIT-Z KID DISPERSIBLE TABLETSDexamethasone acetate
go.drugbank.com/drugs/DB14649ApprovedInvestigationalVet approved[A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues to be administered for a large variety of inflammatory conditions. … In a June 16 2020 press release highlighting early results of a clinical trial, Randomized Evaluation of COVID-19 Therapy (RECOVERY), it was reported that dexamethasone reduced COVID-19 deaths by approximately
Mixtures: BAYCUTEN® N CREMA, BAYCUTEN® N CREMAGadopiclenol
go.drugbank.com/drugs/DB17084ApprovedInvestigational[A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA. … [L43817] In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnIt is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic
Triprolidine
go.drugbank.com/drugs/DB00427ApprovedFirst generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.
Mixtures: Poly Hist NC